Table 1 Baseline demographic data of study population group by parecoxib
Clinical features | Control Group(n = 3198) | Parecoxib Group(n = 344) | P |
|---|---|---|---|
Age (year) | 45.30 ± 9.53 | 45.15 ± 9.81 | 0.921 |
BMI | 22.68 ± 6.35 | 21.96 ± 2.73 | 0.049 |
eGFR | 98.85 ± 21.02 | 100.14 ± 21.55 | 0.270 |
Alcohol consumption | 39 (1.22%) | 3 (0.87%) | 0.572 |
Anemia | 648 (20.26%) | 59 (17.15%) | 0.170 |
Hypertension | 714 (22.33%) | 57 (16.57%) | 0.014 |
Diabetes mellitus | 169 (5.28%) | 14 (4.07%) | 0.333 |
ACEI | 57 (1.78%) | 5 (1.45%) | 0.659 |
ARB | 34 (1.06%) | 2 (0.58%) | 0.397 |
CCB | 426 (13.32%) | 28 (8.14%) | 0.006 |
Diuretics | 35 (1.09%) | 4 (1.16%) | 0.908 |
ASA grade | 0.932 | ||
I–II | 2572 (80.43%) | 276 (80.23%) | |
III–V | 626 (19.57%) | 68 (19.77%) | |
Operative time (min) | < 0.001 | ||
≤ 60 | 442 (13.82%) | 27 (7.85%) | |
61–120 | 841 (26.30%) | 75 (21.80%) | |
121–180 | 812 (25.39%) | 98 (28.49%) | |
> 180 | 1103 (34.49%) | 144 (41.86%) | |
Intraoperative erythrocyte Transfusion, mL (%) | 0.396 | ||
< 100 | 2465 (77.08%) | 315 (77.91%) | |
100–600 | 355 (11.10%) | 29 (8.43%) | |
601–1000 | 173 (5.41%) | 22 (6.40%) | |
> 1000 | 205 (6.41%) | 25 (7.27%) | |
Intraoperative hemorrhage, mL (%) | 0.004 | ||
< 100 | 1030 (32.21%) | 81 (23.55%) | |
100–600 | 1728 (54.03%) | 205 (59.59%) | |
601–1000 | 236 (7.38%) | 26 (7.56%) | |
> 1000 | 204 (6.38%) | 32 (9.30%) | |
Intraoperative hypotension | 345 (10.79%) | 47 (13.66%) | 0.216 |
In fluid amount (10 mL/24 h) | 937.50 (625.00–1369.79) | 1083.33 (666.67–1500.00) | < 0.001 |
Out fluid amount (10 mL/24 h) | 333.33 (145.83–541.67) | 291.67 (125.00–479.17) | 0.004 |